Compare Ascendis Pharma A/S (ASND) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lamb Weston Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lamb Weston Holdings Inc trades at $46.47 (market cap $6.41B). The key difference: Ascendis Pharma A/S is far larger — about 2.8× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 3.27% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LW | |
|---|---|---|
Market Cap | $17.74B | $6.41B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $66.57 |
52-Week Low | $163.32 | $38.48 |
Enterprise Value | $18.11B | $10.38B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lamb Weston (LW) trades at $46.45, up 2.67% today, with a bullish technical signal and consistent earnings beats. The stock shows strong operational cash flow of $868.3M in 2025 and a P/E of 21.81, while recent news highlights its 'Focus to Win' strategy gaining traction. Support sits at $45 with resistance at $46.
Outlook remains positive with a $49.33 consensus price target, though net income declined to $357.2M in 2025. Risks include a pending class action lawsuit and margin pressures, but cost-saving initiatives and activist investor involvement support upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
